Other News To Note
Tuesday, March 26, 2013
United Therapeutics Corp., of Silver Spring, Md., said it received a second complete response letter (CRL) from the FDA, declining to approve its new drug application (NDA) for treprostinil diolamine extended-release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension (PAH).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.